D'Andrea A D
Division of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Cancer Surv. 1992;15:19-36.
Friend virus induced erythroleukaemia can be conveniently divided into a first stage and a second stage. The first stage results from the mitogenic stimulation of EPO-R by gp55. In the second stage, multiple proviral integrations appear to result in further transformation of the SFFV infected erythroblast to a leukaemogenic state. The first stage results from EPO-R activation. After retroviral entry, mediated through an unknown receptor, and after cDNA synthesis and proviral integration, viral proteins are synthesized. Gp55 binds and activates EPO-R. A small but measurable amount of gp55-EPO-R complex is transported to the cell surface (Casadewall et al, 1991). In the presence of helper virus, the defective SFFV genome is packaged and released for subsequent rounds of infection. During the first stage, erythroblasts proliferate but are not tumorigenic. During the second stage of Friend disease, subsequent infections result in further proviral integrations in the host genome. Some of these integrations result in increased Spi-1 expression, whereas others result in decreased p53 expression. These events appear to account for the leukaemogenic properties of cells at this stage, 4-6 weeks after the initial SFFV infection. The interaction between EPO-R and gp55 persists at this later stage, although its contribution to the malignant phenotype of the MEL cells is not known. The sequence of events during stage 1 and stage 2 does not appear to have absolute requirements. Starting with IL-3 dependent immortalized Ba/F3 cells, which already have some unknown proliferative mutation (Mathey-Prevot et al, 1986), gp55 and EPO-R can subsequently be introduced, resulting in tumorigenicity (Li et al, 1990). The primary focus of this review has been the early mitogenic stage of Friend disease. Several concepts have emerged regarding the interaction between gp55 and EPO-R. The interaction between the polypeptides is highly specific, occurs in the extracytoplasmic regions and the transmembrane region of the polypeptides and occurs within the same cell, not via cell-cell contact. Both EPO and gp55 activate EPO-R, via different binding sites, resulting in increased cellular tyrosine kinase activity. The first stage of Friend disease is an example of how a non-oncogene bearing retrovirus can induce leukaemia. The env gene of the SFFV is not a classical oncogene. It does not appear to be derived from a normal cellular proto-oncogene. The interaction of gp55 and EPO-R therefore supports the "receptor mediated leukaemogenesis" hypothesis (McGrath and Weissman, 1978, 1979).(ABSTRACT TRUNCATED AT 400 WORDS)
Friend病毒诱导的红白血病可方便地分为第一阶段和第二阶段。第一阶段是由gp55对促红细胞生成素受体(EPO-R)的促有丝分裂刺激所致。在第二阶段,多个前病毒整合似乎导致感染SFFV的成红细胞进一步转化为致白血病状态。第一阶段是由EPO-R激活引起的。逆转录病毒通过未知受体进入细胞后,经过cDNA合成和前病毒整合,合成病毒蛋白。Gp55结合并激活EPO-R。少量但可测量的gp55-EPO-R复合物被转运到细胞表面(卡萨德瓦尔等人,1991年)。在辅助病毒存在的情况下,缺陷性SFFV基因组被包装并释放,用于后续的感染循环。在第一阶段,成红细胞增殖但不具有致瘤性。在Friend病的第二阶段,后续感染导致宿主基因组中进一步的前病毒整合。其中一些整合导致Spi-1表达增加,而另一些则导致p53表达降低。这些事件似乎解释了在最初SFFV感染后4至6周这个阶段细胞的致白血病特性。EPO-R与gp55之间的相互作用在这个后期阶段持续存在,尽管其对MEL细胞恶性表型的贡献尚不清楚。第一阶段和第二阶段的事件顺序似乎没有绝对要求。从已经有一些未知增殖突变的依赖白细胞介素-3永生化的Ba/F3细胞开始(马泰-普雷沃特等人,1986年),随后可以引入gp55和EPO-R,从而导致致瘤性(李等人,1990年)。本综述的主要重点是Friend病的早期促有丝分裂阶段。关于gp55与EPO-R之间的相互作用已经出现了几个概念。多肽之间的相互作用具有高度特异性,发生在多肽的胞外区域和跨膜区域,并且发生在同一细胞内,不是通过细胞间接触。EPO和gp55都通过不同的结合位点激活EPO-R,导致细胞酪氨酸激酶活性增加。Friend病的第一阶段是一个无致癌基因的逆转录病毒如何诱导白血病的例子。SFFV的env基因不是一个经典的致癌基因。它似乎不是来自正常细胞原癌基因。因此,gp55与EPO-R的相互作用支持“受体介导的白血病发生”假说(麦格拉思和魏斯曼,1978年、1979年)。(摘要截短至400字)